Navigation Links
Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018
Date:11/9/2009

WALTHAM, Mass., Nov. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment. Continued uptake of Herceptin and Tykerb/Tyverb and the expected launches of three new therapies will drive sales of HER2-targeting agents to grow by 3.3 percent per year from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Breast Cancer finds that significant declines in sales in the hormonal therapy and chemotherapy segments of the market will be offset by a 1.2 percent annual increase in breast cancer incidence in the world's major markets and by the launch and uptake of premium-priced agents. Emerging HER2-targeting therapies that are expected to launch by 2018 include Roche/Chugai's Omnitarg, Roche's T-DM1 and Wyeth's HKI-272.

The report also finds that sales of Roche/Chugai's Avastin for breast cancer will increase by four percent from 2008 to 2018, largely owing to greater uptake by patients with metastatic disease.

"Since its approval, Avastin has garnered substantial patient share in metastatic breast cancer, particularly in the metastatic triple-negative and metastatic HR-refractory treatment settings, where there is a significant need for effective therapeutic options," said Decision Resources Analyst Niamh Murphy, Ph.D. "However, many of the physicians we interviewed, particularly in Europe, are not very enthusiastic about Avastin for breast cancer because they consider its cost-benefit profile suboptimal."

According to the report, experts are enthusiastic about the launch and uptake of a novel class of breast cancer
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Recession Continues to Depress Sales at Allied Healthcare Products
2. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
3. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
4. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
5. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
6. HeartSine and Your Safety Company to Donate a Portion of Sales Proceeds to Sudden Cardiac Arrest Foundation
7. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
8. Biosimilar Insulins and Insulin Analogues Stand to Erode $6.1 Billion in Brand Sales in the U.S. and Europe by 2018
9. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
10. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
11. EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 U.S. spending on ... complex diseases such as cancer, multiple sclerosis and rheumatoid ... the end of 2015, according to a forecast released ... (Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we ... and health plans to act so they can continue ...
(Date:5/21/2013)... , May 21, 2013 Reportlinker.com ... is available in its catalogue: ... Reimbursement Scenario for Medical Devices in the ...   Changing Regulatory and ... US Market   ...
(Date:5/21/2013)... 21, 2013  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization ... acute and breakthrough pain, today announced top-line ... 3 study of its investigational sublingual Sufentanil ... the primary efficacy endpoint was achieved.  The ...
Breaking Medicine Technology:U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
(Date:5/21/2013)... 2013 Swimsuit season is almost here. The ... products has begun with a 35% discount. , Cellulite forms ... women get the dreaded cellulite even if they are in ... where they have been stored as toxic lymph and smashed ... fixes, a specific program that works to dissolve the toxins ...
(Date:5/21/2013)... Feed additives have now become an essential ... Most of the feed additives are used in micro ... powders. There are variety of feed additives available that ... the type of animal and feed. Nutritional feed additives ... nutrition to the animal in order to gain lean ...
(Date:5/21/2013)... (May 22, 2013)Today the George Washington (GW) ... Services (SPHHS) announced the launch of the ... Health, a collaboration between SPHHS, the Maryland ... other community partners. This university-community partnership aims ... affect Latino communities through research, mutual capacity ...
(Date:5/21/2013)... Medical Ministry International announced today that ... by GreatNonprofits , the leading provider of user reviews ... a Top-Rated 2013 Nonprofit,” says Samuel Smith, MMI CEO. ... 3000 Volunteers and Staff serving in 22 countries around the ... those that have seen our work first hand and wanted ...
(Date:5/21/2013)... Diego, CA (PRWEB) May 21, 2013 ... adding materials showing how to use 17 DISC applications ... is a natural progression. , The July 25 ... feature the top 17 ways of applying DISC. The ... DISC certified graduates. The user-friendly DISC training ...
Breaking Medicine News(10 mins):Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4
... regional pain syndrome is a neurological disorder caused by continuous ... sense pain. // ,This syndrome includes all the post-traumatic ... injury has healed. But the causes of the symptoms of ... the fact that there are very few objective findings, diagnosis ...
... British Prime Minister Tony Blair today formally inducted 11 private ... further step towards increasing competition in the health sector. //Mr ... members at a summit held at Downing Street to mark ... signed a document pledging to work as partners towards 'future ...
... is the key to weight loss a new study says ... //, ,This study comes from the Canadian Institute for ... work can help make or break our battle against the ... CIHI's Canadian Population Health Initiative, "We see that the majority ...
... pollution in the air now that if it weren't for ... -Robert Orben // ,The order of the ... Clemenceau to be sent back to France, represents the overall ... The order has been issued following dismissal of the proposed ...
... profound impact on either couple, men seem to be more ... Christakis and his research team from Harvard Medical School. ... spouse on the risk of illness in the other partner ... elderly couples. ,They found that when a spouse ...
... at the Washington Hospital Center studied the use of ... blocked arteries. // ,These blocked arteries are ... as it leads to devastating complications such as amputation. ... high blood pressure are at high risk for losing ...
Cached Medicine News:Health News:Location largely affects weight 2Health News:The Return Of The Clemenceau: Happy India 2Health News:Laser Used To Clear Blocked Arteries Preventing Amputation, 2
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Provides basic reduction capabilities for angulation, rotation and length. Ball joint design offers fracture reduction in all planes....
... The Holding Clamps have a slender design ... sequential tensioning of Kirschner wires. The Connecting ... Fiber Rods and/or Connecting Bar. Uses 3.0 ... tip Kirschner wires eliminate need to predrill ...
The Elbow Fixator has ontrolled movement about the axis of rotation of the elbow joint. It is minimally invasive and rapidly applied....
Medicine Products: